{"id":"W3112327018","doi":"10.1016/j.jval.2020.08.462","title":"PCN325 Health Utility in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) Patients - Results of a Phase II Trial with ORAL Selinexor","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Adverse effect; Refractory (planetary science); Population; Progressive disease; Oncology; Disease; Diffuse large B-cell lymphoma; Lymphoma; Environmental health","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001790889,0.0009828855,0.001232676,0.0003082393,0.0002271432,0.0009504818,0.000596956,0.0009998879,0.002934387],"category_scores_gemma":[0.0009631554,0.0002856064,0.00134514,0.0002691148,0.001167423,0.0009613603,0.0003964501,0.002725443,0.0005048474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001050708,"about_ca_system_score_gemma":0.0007821729,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001014432,"about_ca_topic_score_gemma":0.002705084,"domain_scores_codex":[0.9995108,0.0002834206,0.00001782088,0.00005516633,0.00003852318,0.0000943085],"domain_scores_gemma":[0.9994426,0.0001439032,0.00009922333,0.00003245445,0.00002341998,0.000258253],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7696747,0.03153487,0.01108963,0.0007504535,0.002398653,0.0002536294,0.0002314772,0.003240245,0.01611818,0.0005572925,0.003714564,0.1604364],"study_design_scores_gemma":[0.5965683,0.3655086,0.02644692,0.0001060218,0.001411268,0.0003113723,0.000160572,0.002491799,0.002622324,0.0005834847,0.003743634,0.00004580123],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936396,0.003001139,0.0001746495,0.0007679026,0.00005424663,0.0003905828,0.0005936456,0.00003789655,0.001340288],"genre_scores_gemma":[0.9943709,0.001906936,0.0004697731,0.0005767115,0.00008962758,0.0003705954,0.001091529,0.00001266963,0.001111242],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002934387,"threshold_uncertainty_score":0.009816527,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05595646326215171,"score_gpt":0.3238289691381307,"score_spread":0.267872505875979,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}